Hypothesis

NAD+ decline during aging activates a hypoxia‑inducible factor‑1α (HIF‑1α) retrograde signal that boosts NAD+ salvage via NAMPT upregulation, representing a compensatory attempt to preserve cellular redox balance. Chronic inflammaging, through NF‑κB‑dependent induction of CD38, suppresses HIF‑1α activity and diverts the NAD+ pool toward degradation, turning a protective feedback into a net loss.

Mechanistic Rationale

• Falling NAD+ reduces SIRT3 activity, leading to mitochondrial hyperacetylation and increased ROS production [1][2].
• Elevated ROS stabilizes HIF‑1α by inhibiting prolyl hydroxylases, even under normoxia.
• HIF‑1α transcriptionally upregulates NAMPT and other NAD+ salvage enzymes, enhancing NAD+ biosynthesis as a homeostatic response [4].
• In parallel, senescent cell‑derived SASP cytokines activate NF‑κB in immune cells, driving CD38 expression [3]. NF‑κB can bind the HIF‑1α promoter and repress its transcription, and also promotes CD38 enzymatic activity.
• Thus, inflammaging creates a dominant catabolic signal that overrides the HIF‑1α‑mediated anabolic checkpoint, resulting in net NAD+ depletion.

Testable Predictions

1. In aged wild‑type mice, nuclear HIF‑1α activity (measured by HIF‑1α target gene expression) will be elevated in tissues with low NAD+ but will be blunted in macrophages due to NF‑κB activation.
2. Genetic deletion of HIF‑1α specifically in myeloid cells will exacerbate CD38 upregulation and accelerate NAD+ decline, whereas myeloid‑specific HIF‑1α overexpression will reduce CD38 expression and preserve NAD+ levels.
3. Pharmacological stabilization of HIF‑1α (e.g., using DMOG) in aged animals will increase NAMPT activity and partially rescue NAD+ levels, even without CD38 inhibition.
4. Conversely, inhibiting NF‑κB in aged mice will lower CD38 expression and augment HIF‑1α‑driven NAMPT transcription, synergistically raising NAD+.

Experimental Design

• Model: C57BL/6 mice aged 20‑24 months; generate myeloid‑specific HIF‑1α floxed mice crossed with LysM‑Cre; include WT littermates as controls.
• Interventions: treat subsets with DMOG (1 mmol/kg i.p. thrice weekly) or with an NF‑κB inhibitor (BAY 11‑7082) for 4 weeks.
• Readouts: NAD+/NADH ratios by LC‑MS; CD38 mRNA and enzyme activity in sorted macrophages; NAMPT protein activity (using fluorometric assay); HIF‑1α target gene expression (VEGF, GLUT1); mitochondrial ROS (MitoSOX); senescence markers (p16^INK4a, SASP cytokines).
• Analysis: Two‑way ANOVA with genotype and treatment as factors; correlation analysis between NAD+ levels and HIF‑1α activity.

Potential Outcomes and Falsifiability

• If myeloid HIF‑1α loss leads to further NAD+ decline and worsened metabolic readouts, the hypothesis gains support.
• If HIF‑1α manipulation does not affect NAD+ or CD38 levels, or if NF‑κB inhibition fails to raise NAD+ despite lowered CD38, the proposed feedback loop would be falsified, suggesting NAD+ loss is driven primarily by CD38 upregulation without a counteracting HIF‑1α arm.
• Rescue of NAD+ by DMOG without CD38 inhibition would demonstrate that boosting salvage can counteract degradation, confirming the compensatory arm.

This framework reframes NAD+ decline as the tipping point of a competing redox‑sensitive signaling network, offering a clear, falsifiable path to test whether boosting the HIF‑1α‑NAMPT axis can mitigate inflammaging‑driven NAD+ loss.